Compare Palantir Technologies Inc (PLTR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Palantir Technologies Inc trades at $200.56 (market cap $466.48B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Palantir Technologies Inc is far larger — about 27.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PLTR | ZBH | |
|---|---|---|
Market Cap | $466.48B | $16.88B |
Volume | 15,675,589 | 1,991,354 |
Sector | Technology | Health |
52-Week High | $207.18 | $103.98 |
52-Week Low | $107.27 | $79.58 |
Typical Hold Time | 78 Days | 89 Days |
Enterprise Value | $457.28B | $23.95B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $194.04, up 1.02% with a bullish technical outlook and strong fundamental momentum. The stock shows robust revenue growth of 56.2% in 2025, reaching $4.48 billion, with net income surging to $1.63 billion. Recent partnerships with Armada for sovereign AI infrastructure and consistent earnings beats highlight operational strength, though valuation metrics remain elevated with a P/E of 165.91.
The outlook remains positive with analyst consensus at Buy (53.84%) and a $191.69 price target. Key opportunities include AI platform expansion and commercial customer growth to 870, while risks involve high valuation sensitivity and competitive pressures. The stock trades near recent highs with support at $191 and resistance at $195.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
